Recent News

• 01.22.2026 - Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
• 01.08.2026 - Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
• 12.04.2025 - Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
• 11.13.2025 - Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
• 11.06.2025 - Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
• 10.08.2025 - Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
• 09.18.2025 - Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

Recent Filings

• 01.12.2026 - 3 Initial statement of beneficial ownership of securities
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.05.2025 - 8-K Current report
• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.13.2025 - S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
• 11.13.2025 - 8-K Current report
• 11.13.2025 - EX-99.1 EX-99.1